Lysoway Therapeutics

Lysoway Therapeutics is an early-stage, private biotech founded in 2021 and based in Cambridge, USA, targeting a novel mechanism in neurodegeneration. The company is developing highly selective agonists for lysosomal ion channels (TRPML1, TMEM175) to correct the dysfunctional autophagy and lysosomal impairment central to diseases like Alzheimer's and Parkinson's. Leveraging proprietary screening and structure-guided design platforms, Lysoway aims to create first-in-class therapeutics that address core cellular pathology. The company is backed by venture capital firms including 3E Bioventures, Oceanpine Capital, and Highlight Capital, and is led by a team with deep expertise in drug discovery and translational sciences.

Proprietary screening platforms and structure-guided design technologies for developing brain-penetrant small-molecule modulators of lysosomal ion channels (e.g., TRPML1, TMEM175).

The field of autophagy/lysosomal modulation is emerging but competitive, with other biotefts and academics exploring related targets (e.g., TFEB). Large pharma's interest in neurodegeneration creates both partnership potential and future competitive threat.